Neuren Pharmaceuticals 미래 성장

Future 기준 확인 1/6

Neuren Pharmaceuticals 의 수익은 연간 5.1% 감소할 것으로 예상되는 반면, 연간 수익은 5.1% 로 증가할 것으로 예상됩니다. 5.1% 연간. EPS는 연간 4.8% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 14% 로 예상됩니다.

주요 정보

5.1%

수익 성장률

4.79%

EPS 성장률

Pharmaceuticals 수익 성장	41.1%
매출 성장률	-5.1%
향후 자기자본 수익률	14.02%
애널리스트 커버리지	Good
마지막 업데이트	09 May 2025

최근 미래 성장 업데이트

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Recent updates

Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth

May 16

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

Apr 23 Strong financial position and partnerships reduce the need for capital raising, protecting margins and earnings.

Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel

Apr 01

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 06

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching

Jan 15

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Nov 11

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Nov 08

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Oct 24

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Aug 29

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Aug 14

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

May 31

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

May 03

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Apr 01

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Mar 05

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Mar 02

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Dec 18

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Sep 02

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Aug 31

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Mar 03

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Jan 07

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

Sep 06

Companies Like Neuren Pharmaceuticals (ASX:NEU) Can Afford To Invest In Growth

May 31

We're Not Worried About Neuren Pharmaceuticals' (ASX:NEU) Cash Burn

Feb 03

Here's Why We're Not At All Concerned With Neuren Pharmaceuticals' (ASX:NEU) Cash Burn Situation

Aug 06

We Think Neuren Pharmaceuticals (ASX:NEU) Can Easily Afford To Drive Business Growth

May 05

Independent Non-Executive Chairman Patrick Donald Davies Just Bought 21% More Shares In Neuren Pharmaceuticals Limited (ASX:NEU)

Feb 19

수익 및 매출 성장 예측

ASX:NEU - 애널리스트의 미래 추정치 및 과거 재무 데이터 (AUD Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2027	176	76	54	47	3
12/31/2026	142	55	23	50	4
12/31/2025	66	16	89	121	4
12/31/2024	217	142	-11	-11	N/A
9/30/2024	205	130	54	54	N/A
6/30/2024	193	117	119	120	N/A
3/31/2024	213	137	152	152	N/A
12/31/2023	232	157	185	185	N/A
9/30/2023	155	106	120	120	N/A
6/30/2023	78	55	54	54	N/A
3/31/2023	47	28	29	29	N/A
12/31/2022	15	0	4	4	N/A
9/30/2022	9	-3	-3	-3	N/A
6/30/2022	3	-7	-10	-10	N/A
3/31/2022	3	-7	-10	-10	N/A
12/31/2021	3	-8	-10	-10	N/A
9/30/2021	2	-10	-10	-10	N/A
6/30/2021	1	-12	-9	-9	N/A
3/31/2021	1	-11	-9	-9	N/A
12/31/2020	1	-9	-8	-8	N/A
9/30/2020	1	-8	-9	-9	N/A
6/30/2020	0	-8	-9	-9	N/A
3/31/2020	0	-9	-10	-10	N/A
12/31/2019	0	-11	-12	-12	N/A
9/30/2019	7	-6	-5	-5	N/A
6/30/2019	14	-1	2	2	N/A
3/31/2019	14	1	4	4	N/A
12/31/2018	14	3	6	6	N/A
9/30/2018	7	3	N/A	0	N/A
6/30/2018	1	3	N/A	-6	N/A
3/31/2018	1	3	N/A	-6	N/A
12/31/2017	1	3	N/A	-6	N/A
9/30/2017	2	-2	N/A	-7	N/A
6/30/2017	3	-8	N/A	-8	N/A
3/31/2017	3	-10	N/A	-10	N/A
12/31/2016	3	-12	N/A	-12	N/A
9/30/2016	2	-14	N/A	-14	N/A
6/30/2016	0	-15	N/A	-17	N/A
3/31/2016	1	-14	N/A	-15	N/A
12/31/2015	2	-13	N/A	-13	N/A
9/30/2015	2	-11	N/A	-11	N/A
6/30/2015	3	-9	N/A	-8	N/A
3/31/2015	3	-9	N/A	-7	N/A
12/31/2014	3	-8	N/A	-6	N/A
9/30/2014	3	-10	N/A	-7	N/A
6/30/2014	3	-12	N/A	-7	N/A

애널리스트 미래 성장 예측

수입 대 저축률: NEU 의 연간 예상 수익 증가율( 5.1% )이 saving rate( 3% 보다 높습니다. ).

수익 vs 시장: NEU 의 연간 수익( 5.1% ) Australian 시장( 11.8% 보다 느리게 성장할 것으로 예상됩니다. 11.8% 연간).

고성장 수익: NEU 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: NEU 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -5.1% ).

고성장 수익: NEU 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -5.1% ).

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: NEU 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 14 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2025/05/23 08:57
장 마감 주가	2025/05/23 00:00
수익	2024/12/31
연간 수익	2024/12/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처는 미국 증권의 예를 사용했습니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 Github에서 확인할 수 있습니다.

애널리스트 출처

Neuren Pharmaceuticals Limited 9 애널리스트 중 7 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Russell Wright	Barclay Pearce Capital Pty Limited
Melissa Benson	Barrenjoey Markets Pty Limited
Thomas Wakim	Bell Potter

Neuren Pharmaceuticals 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Consensus EPS estimates increase by 27%

Price target decreased by 7.5% to AU$24.97

Consensus revenue estimates fall by 46%

Consensus revenue estimates increase by 17%, EPS downgraded

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

Price target decreased by 7.5% to AU$26.54

Recent updates

Neuren Pharmaceuticals Limited (ASX:NEU) Shares Fly 30% But Investors Aren't Buying For Growth

Consensus EPS estimates increase by 27%

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Neuren Pharmaceuticals Limited, Annual General Meeting, May 27, 2025

DAYBUE And NNZ-2591 Will Expand Markets While Facing Regulatory Risks

Independent Non-Executive Director recently bought AU$153k worth of stock

Investor sentiment deteriorates as stock falls 20%

Investors Don't See Light At End Of Neuren Pharmaceuticals Limited's (ASX:NEU) Tunnel

Price target decreased by 7.5% to AU$24.97

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 46%

Neuren Pharmaceuticals Limited to Report Fiscal Year 2024 Results on Feb 28, 2025

A Look At The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Investor sentiment improves as stock rises 27%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Is Well Worth Watching

Investor sentiment deteriorates as stock falls 26%

Now 24% undervalued

New Forecasts: Here's What Analysts Think The Future Holds For Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited's (ASX:NEU) Shares Climb 26% But Its Business Is Yet to Catch Up

Investor sentiment improves as stock rises 17%

Consensus revenue estimates increase by 17%, EPS downgraded

New major risk - Revenue and earnings growth

Calculating The Intrinsic Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Just Missed Earnings - But Analysts Have Updated Their Models

First half 2024 earnings: EPS misses analyst expectations

Pinning Down Neuren Pharmaceuticals Limited's (ASX:NEU) P/S Is Difficult Right Now

Price target decreased by 7.5% to AU$26.54

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 15%

Here's Why We Think Neuren Pharmaceuticals (ASX:NEU) Might Deserve Your Attention Today

Price target increased by 7.9% to AU$28.19

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome

Getting In Cheap On Neuren Pharmaceuticals Limited (ASX:NEU) Is Unlikely

Neuren Pharmaceuticals Limited, Annual General Meeting, May 28, 2024

An Intrinsic Calculation For Neuren Pharmaceuticals Limited (ASX:NEU) Suggests It's 41% Undervalued

Consensus revenue estimates increase by 15%

Forecast: Analysts Think Neuren Pharmaceuticals Limited's (ASX:NEU) Business Prospects Have Improved Drastically

Here's Why Neuren Pharmaceuticals (ASX:NEU) Has Caught The Eye Of Investors

Neuren Pharmaceuticals Limited to Report Q4, 2023 Results on Feb 29, 2024

Neuren Pharmaceuticals Limited's (ASX:NEU) 51% Jump Shows Its Popularity With Investors

Price target increased by 27% to AU$24.22

Investor sentiment improves as stock rises 40%

Consensus EPS estimates fall by 11%

Investor sentiment improves as stock rises 20%

Now 23% undervalued after recent price drop

Price target increased by 18% to AU$19.14

Now 20% undervalued after recent price drop

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Neuren Pharmaceuticals Limited (ASX:NEU) Revenues

Now 25% undervalued after recent price drop

Calculating The Fair Value Of Neuren Pharmaceuticals Limited (ASX:NEU)

Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023

Neuren Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 28, 2023

Now 21% undervalued

Consensus EPS estimates fall by 12%

Price target increased by 8.3% to AU$15.07

Independent Non-Executive Director recently sold AU$15m worth of stock

Consensus revenue estimates increase by 12%, EPS downgraded

Price target increased by 18% to AU$10.60

Consensus EPS estimates fall by 14%

This Just In: Analysts Are Boosting Their Neuren Pharmaceuticals Limited (ASX:NEU) Outlook for This Year

Price target increased by 12% to AU$8.99

Neuren Pharmaceuticals Limited Announces Prader-Willi Syndrome IND for NNZ-2591 Approval by FDA

Neuren Pharmaceuticals (ASX:NEU) Is In A Strong Position To Grow Its Business

Neuren Pharmaceuticals Submits Investigational New Drug & First Patients Complete Phase 2 Trials

Price target increased to AU$7.83

Price target increased to AU$7.83

Price target increased to AU$7.37